First Time Loading...

Cyclo Therapeutics Inc
NASDAQ:CYTH

Watchlist Manager
Cyclo Therapeutics Inc Logo
Cyclo Therapeutics Inc
NASDAQ:CYTH
Watchlist
Price: 1.26 USD -2.33% Market Closed
Updated: Apr 29, 2024
Section:
 

Wall Street
Price Targets

CYTH Price Targets Summary
Cyclo Therapeutics Inc

Wall Street analysts forecast CYTH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CYTH is 4.08 USD with a low forecast of 4.04 USD and a high forecast of 4.2 USD.

CYTH Lowest Forecast
Wall Street Target
4.04 USD
221% Upside
CYTH Average Forecast
Wall Street Target
4.08 USD
224% Upside
CYTH Highest Forecast
Wall Street Target
4.2 USD
233% Upside
Lowest
Price Target
4.04 USD
221% Upside
Average
Price Target
4.08 USD
224% Upside
Highest
Price Target
4.2 USD
233% Upside
Cyclo Therapeutics Inc Competitors:
Price Targets
H
042520
Hans Biomed Corp
182% Upside
TWST
Twist Bioscience Corp
30% Upside
VRTX
Vertex Pharmaceuticals Inc
20% Upside
STOK
Stoke Therapeutics Inc
95% Upside
H
042520
Hans Biomed Corp
182% Upside
TWST
Twist Bioscience Corp
30% Upside
VRTX
Vertex Pharmaceuticals Inc
20% Upside
STOK
Stoke Therapeutics Inc
95% Upside
INCY
Incyte Corp
49% Upside
IGMS
IGM Biosciences Inc
130% Upside
300896
Imeik Technology Development Co Ltd
73% Upside
COX
Nicox SA
401% Upside

Revenue
Forecast

Revenue Estimate
Cyclo Therapeutics Inc

For the last 8 years the compound annual growth rate for Cyclo Therapeutics Inc's revenue is 2%. The projected CAGR for the next 2 years is 430%.

2%
Past Growth
430%
Estimated Growth
Estimates Accuracy
-12%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Cyclo Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Cyclo Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-80%
Average Miss
What are analyst estimates?

See Also

Summary
CYTH intrinsic value, competitors valuation, and company profile.
DCF Valuation
CYTH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CYTH stock valuation using valuation multiples.
Wall Street Estimates
CYTH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CYTH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CYTH's stock price target?
Price Target
4.08 USD

According to Wall Street analysts, the average 1-year price target for CYTH is 4.08 USD with a low forecast of 4.04 USD and a high forecast of 4.2 USD.

What is Cyclo Therapeutics Inc's Revenue forecast?
Projected CAGR
430%

For the last 8 years the compound annual growth rate for Cyclo Therapeutics Inc's revenue is 2%. The projected CAGR for the next 2 years is 430%.

ALPHA SPREAD
Join more than 132,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.